1Moorhead JF,Chan MK, El-Nahas M,et al. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease [J]. Lancet. 1982,2(8311) :1309-1311.
2Llisterri Caro JL, Gorriz Teruel JL, Alonso Moreno FJ, et al. Prevalence of undetected chronic kidney disease in dyslipidemic population treated in primary care. LIPICAP study[J]. Med Clin (Barc), 2008,130 (4) : 127-132.
3Chan CM. Hyperlipidaemia in chronic kidney disease[J]. Ann Acad Med Singapore, 2005,34 (1) : 31-35.
4Kasiske BL. Hyperlipidemia in patients with chronic renal disease[J]. Am J Kidney Dis,1998,32(Supple) :142-156.
5Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms,and potential consequences[J]. Am J Physiol Renal Physiol,2006,290(2) :F262-272.
6Moliteh ME. Management of dyslipidemias in patients with diabetes and chronic kidney disease[J]. Clin J Am Soe Nephrol, 2006,1(5) ~ 1090-1099.
7Sawara Y, Takei T, Uchida K, et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease[J]. InternMed,2008,47(17):1505- 1510.
9Tsimihodimos V,Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease., an approach to pathogenesis and treatment[J]. Am J Nephrol,2008,28(6) : 958-973.
